Exicure (XCUR) Revenue & Revenue Breakdown
Exicure Revenue Highlights
00
Exicure Revenue by Period
Exicure Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $28.83M | -6068.12% |
| 2021-12-31 | $-483.00K | -102.91% |
| 2020-12-31 | $16.61M | 1181.87% |
| 2019-12-31 | $1.30M | 998.31% |
| 2018-12-31 | $118.00K | -98.79% |
| 2017-12-31 | $9.72M | 838.13% |
| 2016-12-31 | $1.04M | -56.62% |
| 2015-12-31 | $2.39M | - |
Exicure generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Exicure Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $500.00K | -3.10% |
| 2023-12-31 | $516.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $21.77M | 980.06% |
| 2022-09-30 | $2.02M | -18.41% |
| 2022-06-30 | $2.47M | -3.66% |
| 2022-03-31 | $2.56M | 21.10% |
| 2021-12-31 | $2.12M | -157.60% |
| 2021-09-30 | $-3.68M | -4754.43% |
| 2021-06-30 | $79.00K | -92.08% |
| 2021-03-31 | $997.00K | 612.14% |
| 2020-12-31 | $140.00K | -94.27% |
| 2020-09-30 | $2.44M | -49.60% |
| 2020-06-30 | $4.85M | -47.22% |
| 2020-03-31 | $9.18M | 2862.26% |
| 2019-12-31 | $310.00K | -41.18% |
| 2019-09-30 | $527.00K | 21.43% |
| 2019-06-30 | $434.00K | 1636.00% |
| 2019-03-31 | $25.00K | 316.67% |
| 2018-12-31 | $6.00K | -89.47% |
| 2018-09-30 | $57.00K | 200.00% |
| 2018-06-30 | $19.00K | -47.22% |
| 2018-03-31 | $36.00K | -98.28% |
| 2017-12-31 | $2.10M | -16.10% |
| 2017-09-30 | $2.50M | -7.35% |
| 2017-06-30 | $2.69M | 10.81% |
| 2017-03-30 | $2.43M | 252.46% |
| 2016-12-31 | $690.00K | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $173.00K | - |
| 2016-03-31 | $173.00K | - |
Exicure generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Exicure Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| SCPH | scPharmaceuticals | $13.59M | $8.05M |
| IKNA | Ikena Oncology | $9.16M | - |
| HSTO | Histogen | $3.77M | $5.00K |
| MRKR | Marker Therapeutics | $3.31M | $1.93M |
| HCWB | HCW Biologics | $2.84M | $426.42K |
| LUMO | Lumos Pharma | $2.05M | $488.00K |
| MIST | Milestone Pharmaceuticals | $1.00M | - |
| CBIO | Gyre Therapeutics | $794.00K | - |
| CYCC | Cyclacel Pharmaceuticals | $420.00K | $10.00 |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| IMNN | Imunon | - | - |
| XCUR | Exicure | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| RNXT | RenovoRx | - | - |
| TPST | Tempest Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| ONCY | Oncolytics Biotech | - | - |
| PTIX | Protagenic Therapeutics | - | $50.29K |
| ENOB | Renovaro Biosciences | - | - |